Sirius Therapeutics is a global clinical-stage biotechnology company dedicated to unlocking the clinical and commercial value of siRNA therapeutics. The Company’s goal is to transform the current standard of care for chronic diseases by developing first-in-class and best-in-class siRNA therapeutics for large unmet global medical needs, a strategy underpinned by three mega-blockbuster franchises, proprietary siRNA technology platform (PEPR) and global partnership and capabilities.
Sirius is focused on three mega-blockbuster franchises, targeting coagulation disorders, cardiometabolic diseases, and obesity.
Sirius Therapeutics was founded in 2021 and is a globally integrated biotechnology company with dual headquarters in San Diego, USA, and Shanghai, China. The Company’s strategic advantage is rooted in a hybrid operational model that seamlessly combines the exceptional early development capacity and cost-efficiency of the Company’s China-based team with the global discovery and regulatory expertise of the U.S.-based team.
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
